Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Elevation Oncology, Inc.
Elevation Oncology, Inc. News
Jun 15, 2025 - globenewswire.com
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)
Jun 12, 2025 - prnewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
Jun 10, 2025 - businesswire.com
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV
Jun 9, 2025 - businesswire.com
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
Elevation Oncology, Inc. Quantitative Score
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Elevation Oncology, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Elevation Oncology, Inc. Financials
Table Compare
Compare ELEV metrics with: | |||
|---|---|---|---|
Earnings & Growth | ELEV | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ELEV | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ELEV | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ELEV | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Elevation Oncology, Inc. Income
Elevation Oncology, Inc. Balance Sheet
Elevation Oncology, Inc. Cash Flow
Elevation Oncology, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Elevation Oncology, Inc. Executives
| Name | Role |
|---|---|
| Mr. Joseph J. Ferra Jr. | Chief Executive Officer, President & Director |
| Ms. Tammy Furlong CPA, P.M.P. | Chief Financial Officer & Secretary |
| Mr. Robert C. Yang | Senior Vice President & General Counsel |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Joseph J. Ferra Jr. | Chief Executive Officer, President & Director | Male | 1975 | 931.58K |
| Ms. Tammy Furlong CPA, P.M.P. | Chief Financial Officer & Secretary | Female | 1972 | -- |
| Mr. Robert C. Yang | Senior Vice President & General Counsel | Male | -- |
Elevation Oncology, Inc. Insider Trades
| Date | 23 Jul |
| Name | Sandler Alan B. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 55000 |
| Date | 23 Jul |
| Name | Sandler Alan B. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 35000 |
| Date | 23 Jul |
| Name | Sandler Alan B. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 35000 |
| Date | 23 Jul |
| Name | Mootz Darcy |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 55000 |
| Date | 23 Jul |
| Name | Mootz Darcy |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 35000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 23 Jul | Sandler Alan B. | Director | Disposed | D-Return | 55000 |
| 23 Jul | Sandler Alan B. | Director | Disposed | D-Return | 35000 |
| 23 Jul | Sandler Alan B. | Director | Disposed | D-Return | 35000 |
| 23 Jul | Mootz Darcy | Director | Disposed | D-Return | 55000 |
| 23 Jul | Mootz Darcy | Director | Disposed | D-Return | 35000 |